Sanofi-Aventis CEO targeting emerging markets, consumer products — everything but blockbusters TRENTON, N.J. – After 20 months running drugmaker Sanofi-Aventis SA, Chris Viehbacher wants to end the roller coaster of revenue peaks and valleys as blockbuster drugs climb to billions in sales and suddenly plummet when generic competition hits. Read more on Minneapolis-St. Paul...
Report: Sanofi-Aventis, Genzyme talk acquisition Shares of Genzyme Corp. soared Friday after a report was published that French pharmaceutical company Sanofi-Aventis is interested in the biotechnology drugmaker. Read more on AP via Yahoo! Finance India, EU to have free trade talks India and the European Union will hold a fresh series of free-trade talks...
Merck Challenges Verdict in Federal FOSAMAX® (alendronate sodium) Trial WHITEHOUSE STATION, N.J.—-Merck & Co., Inc. today said it is challenging the decision returned by a New York jury in the retrial of a federal FOSAMAX case, Boles v. Merck. This case was the Plaintiffs’ Steering Committee’s top choice to take to trial and involved...
Column: Ranbaxy needs a booster By failing to launch the generic version of the blockbuster urinary drug Flomax in the US on March 2, Ranbaxy has not… Read more on Express India Merck, Sanofi combining animal medicine divisions Two of the world’s biggest pharmaceutical companies said Tuesday they are uniting their animal health businesses...
Sanofi-Aventis, Merck to Combine Animal Health Units (Update3) March 9 (Bloomberg) — Sanofi-Aventis SA and Merck & Co. will combine their veterinary medicine units to create the world’s largest animal-health business with combined sales of more than $5 billion and 14,000 employees. Read more on Bloomberg Press Release Salix Pharmaceuticals Ltd. Posted on:10 Mar...
Powered by Yahoo! Answers